// App-Quantinova.ai

: The IG/TR Next Generation Marker Screening Developed within Euroclonality-NGS Consortium Is Successful in 94% of Acute Lymphoblastic Leukemia Samples

Researchers

Presenter

  • Michaela Kotrova

Principal Investigators

  • Henrik Knecht

  • Dietrich Herrmann

  • Martin Schwarz

  • Karin Olsen

  • Heiko Trautmann

  • Nicola Goekbuget

  • Christiane Pott

  • Nikos Darzentas

  • Monika Brggemann

Medical Centers

  • Internal Medicine 2, Hematology Laboratory, University of Kiel / UKSH, Kiel, Germany

  • Department of Internal Medicine I, Universitätsklinikum Schleswig‐Holstein (UKSH), Campus Kiel, Kiel, Germany

  • Department of Medicine, University Medical Center Schleswig-Holstein, Kiel, Germany

  • Department of General Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany

  • Department of Hematology/Oncology, Goethe-University Hospital Frankfurt, Frankfurt Am Main, Germany

  • CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic

Locations

  • Germany

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • T cell receptor delta locus

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved